<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">632903</article-id><article-id pub-id-type="doi">10.26442/20751753.2024.2.202719</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Diagnosis and treatment of vascular cognitive impairment, the use of citicoline: A review</article-title><trans-title-group xml:lang="ru"><trans-title>Диагноз и лечение сосудистых когнитивных нарушений, применение цитиколина</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1992-7960</contrib-id><name-alternatives><name xml:lang="en"><surname>Parfenov</surname><given-names>Vladimir A.</given-names></name><name xml:lang="ru"><surname>Парфенов</surname><given-names>Владимир Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф., зав. каф. нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского</p></bio><email>vladimirparfenov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-05-09" publication-format="electronic"><day>09</day><month>05</month><year>2024</year></pub-date><volume>26</volume><issue>2</issue><issue-title xml:lang="en">Neurology and rheumatology</issue-title><issue-title xml:lang="ru">Неврология и ревматология</issue-title><fpage>112</fpage><lpage>116</lpage><history><date date-type="received" iso-8601-date="2024-05-27"><day>27</day><month>05</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-05-27"><day>27</day><month>05</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/632903">https://consilium.orscience.ru/2075-1753/article/view/632903</self-uri><abstract xml:lang="en"><p>The management of patients with cognitive impairment (CI) is one of the urgent problems of modern medicine. Vascular CI (VCI) is the second most common cause of dementia after Alzheimer's disease. The diagnosis of VCI is based on the results of a neuropsychological examination, the presence of clinical and neuroimaging signs of cerebrovascular disease, and the absence of data for other causes of CI. Socio-psychological methods, stroke prevention, correction of vascular risk factors, and stimulation of patients to regular physical and mental activity are of leading importance in the management of patients with VCI. The effectiveness and safety of citicoline in VCI are discussed.</p></abstract><trans-abstract xml:lang="ru"><p>Ведéние пациентов с когнитивными нарушениями (КН) является одной из актуальных проблем современной медицины. Сосудистые КН (СКН) представляют вторую по частоте после болезни Альцгеймера причину деменции. Диагноз СКН основывается на результатах нейропсихологического обследования, наличии клинических и нейровизуализационных признаков цереброваскулярного заболевания, отсутствии данных, свидетельствующих о других причинах КН. Основополагающее значение при ведéнии пациентов с СКН имеют социально-психологические методы, профилактика инсульта, коррекция сосудистых факторов риска, стимулирование пациентов к регулярной физической и умственной активности. Обсуждаются вопросы эффективности и безопасности цитиколина при СКН.</p></trans-abstract><kwd-group xml:lang="en"><kwd>dyscirculatory encephalopathy</kwd><kwd>chronic cerebral ischemia</kwd><kwd>stroke</kwd><kwd>vascular cognitive impairment</kwd><kwd>citicoline</kwd><kwd>Neipilept®</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дисциркуляторная энцефалопатия</kwd><kwd>хроническая ишемия головного мозга</kwd><kwd>инсульт</kwd><kwd>сосудистые когнитивные нарушения</kwd><kwd>цитиколин</kwd><kwd>Нейпилепт®</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. Geneva: World Health Organization, 2019. Available at: https://www.who.int/publications/i/item/9789241550543. Accessed: 20.02.2024.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Verdelho A, Wardlaw J, Pavlovic A, et al. Cognitive impairment in patients with cerebrovascular disease: A white paper from the links between stroke ESO Dementia Committee. Eur Stroke J. 2021;6(1):5-17. DOI:10.1177/23969873211000258</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Gorelick PB, Scuteri A, Black SE, et al.; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-713. DOI:10.1161/STR.0b013e3182299496</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sachdev P, Kalaria R, O’Brien J, et al.; Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: A VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-18. DOI:10.1097/WAD.0000000000000034</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zanon Zotin MC, Sveikata L, Viswanathan A, Yilmaz P. Cerebral small vessel disease and vascular cognitive impairment: From diagnosis to management. Curr Opin Neurol. 2021;34(2):246-57. DOI:10.1097/WCO.0000000000000913</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Casolla B, Caparros F, Cordonnier C, et al. Biological and imaging predictors of cognitive impairment after stroke: A systematic review. J Neurol. 2019;266(11):2593-604. DOI:10.1007/s00415-018-9089-z</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Levine DA, Galecki AT, Langa KM, et al. Trajectory of cognitive decline after incident stroke. JAMA. 2015;314(1):41-51. DOI:10.1001/jama.2015.6968</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sexton E, McLoughlin A, Williams DJ, et al. Systematic review and meta-analysis of the prevalence of cognitive impairment no dementia in the first year post-stroke. Eur Stroke J. 2019;4(2):160-71. DOI:10.1177/2396987318825484</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Парфенов В.А. Сосудистые когнитивные нарушения и хроническая ишемия головного мозга (дисциркуляторная энцефалопатия). Неврология, нейропсихиатрия, психосоматика. 2019;11(Прил. 3):61-7 [Parfenov VA. Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy). Neurology, Neuropsychiatry, Psychosomatics. 2019;11(Suppl. 3):61-7 (in Russian)]. DOI:10.14412/2074-2711-2019-3S-61-67</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Levit A, Hachinski V, Whitehead SN. Neurovascular unit dysregulation, white matter disease, and executive dysfunction: The shared triad of vascular cognitive impairment and Alzheimer disease. Geroscience. 2020;42(2):445-65. DOI:10.1007/s11357-020-00164-6</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Vasquez BP, Zakzanis KK. The neuropsychological profile of vascular cognitive impairment not demented: A meta-analysis. J Neuropsychol. 2015;9(1):109-36. DOI:10.1111/jnp.12039</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(25):3326-44. DOI:10.1016/j.jacc.2019.04.034</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Парфенов В.А., Коберская Н.Н. Болезнь Альцгеймера. М.: ИМА-ПРЕСС, 2022 [Parfenov VA, Koberskaia NN. Bolezn’ Al’tsgeimera. Moscow: IMA-PRESS, 2022 (in Russian)].</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Парфенов В.А. Ведение пациента с когнитивными нарушениями. Неврология, нейропсихиатрия, психосоматика. 2023;15(1):97-102 [Parfenov VA. Management of patients with cognitive impairment. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(1):97-102 (in Russian)]. DOI:10.14412/2074-2711-2023-1-97-102</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Skrobot OA, Black SE, Chen C, et al.; VICCCS group. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement. 2018;14(3):280-92. DOI:10.1016/j.jalz.2017.09.007</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Парфенов В.А. Дисциркуляторная энцефалопатия и сосудистые когнитивные расстройства. М.: ИМА-ПРЕСС, 2017 [Parfenov VA. Distsirkuliatornaia entsefalopatiia i sosudistye kognitivnye rasstroistva. Moscow: IMA-PRESS, 2017 (in Russian)].</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-46. DOI:10.1016/ S0140-6736(20)30367-6</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Hallam B, Rees J, Petersen I, et al. How are people with mild cognitive impairment or subjective memory complaints managed in primary care? A systematic review. Fam Pract. 2021;38(5):669-83. DOI:10.1093/fampra/cmab014</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet. 2015;385(9984):2255-63. DOI:10.1016/S0140-6736(15)60461-5</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Barnes JN. Exercise, cognitive function, and aging. Adv Physiol Educ. 2015;39(2):55-62. DOI:10.1152/advan.00101.2014</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lewis M, Peiris CL, Shields N. Long-term home and community-based exercise programs improve function in community-dwelling older people with cognitive impairment: A systematic review. J Physiotherapy. 2017;63(1):23-9. DOI:10.1016/j.jphys.2016.11.005</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Liu-Ambrose T, Best JR, Davis JC, et al. Aerobic exercise and vascular cognitive impairment: A randomized controlled trial. Neurology. 2016;87(20):2082-90. DOI:10.1212/WNL.0000000000003332</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Xu W, Wang HF, Wan Y, et al. Leisure time physical activity and dementia risk: a dose-response meta-analysis of prospective studies. BMJ Open. 2017;7(10):e014706. DOI:10.1136/bmjopen-2016-014706</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Blumenthal JA, Smith PJ, Mabe S, et al. Longer term effects of diet and exercise on neurocognition: 1-year follow-up of the ENLIGHTEN trial. J Am Geriatr Soc. 2020;68(3):559-68. DOI:10.1111/jgs.16252</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: A systematic review. Epidemiology. 2013;24(4):479-89. DOI:10.1097/EDE.0b013e3182944410</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Wu L, Sun D. Adherence to Mediterranean diet and risk of developing cognitive disorders: An updated systematic review and meta-analysis of prospective cohort studies. Sci Rep. 2017;7:41317. DOI:10.1038/srep41317</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Chalfont G, Milligan C, Simpson J. A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia (London). 2020;19(4):1086-130. DOI:10.1177/1471301218795289</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: A network meta-analysis. J Hypertens. 2013;31(6):1073-82. DOI:10.1097/HJH.0b013e3283603f53</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Peng J, Lu F, Wang Z, et al. Excessive lowering of blood pressure is not beneficial for progression of brain white matter hyperintensive and cognitive impairment in elderly hypertensive patients: 4-year follow-up study. J Am Med Dir Assoc. 2014;15(12):904-10. DOI:10.1016/j.jamda.2014.07.005</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;4:CD004034. DOI:10.1002/14651858.CD004034.pub3</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Spinelli C, Fara De Caro M, Schirosi G. Impaired cognitive executive dysfunction in adult treated hypertensives with a confirmed diagnosis of poorly controlled blood pressure. Int J Med Sci. 2014;11(8):771-8. DOI:10.7150/ijms.8147</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(3):169-83. DOI:10.1177/1533317511402051</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Pizzi C, Rutjes AW, Costa GM, et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972-9. DOI:10.1016/j.amjcard.2010.11.017</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: The Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5(Suppl. 1):S5. DOI:10.1186/alzrt201</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for vascular cognitive impairment. CNS Drugs. 2017;31(9):759-76. DOI:10.1007/s40263-017-0459-3</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269. DOI:10.1002/14651858.CD000269.pub2</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Alvarez-Sabin J, Ortega G, Jacas C. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis. 2013;35(2):146-54. DOI:10.1159/000346602</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Cotroneo AM, Castagna A, Putignano S. Effectiveness and safety of citicoline in mild vascular cog- nitive impairment: The IDEALE study. Clin Interv Aging. 2013;8:131-7. DOI:10.2147/CIA.S38420</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in elderly patients affected with Dementia study. Clin Drug Investig. 2016;36(12):1059-65. DOI:10.1007/s40261-016-0454-3</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and memory function in healthy older adults: A randomized, double-blind, placebo-controlled clinical trial. J Nutr. 2021;151(8):2153-60. DOI:10.1093/jn/nxab119</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Шутеева Т.В. Современные подходы к вопросам коррекции когнитивных и эмоциональных расстройств у пациентов с хронической ишемией головного мозга. РМЖ. 2017;21:1507-10 [Shuteeva TV. Modern approaches to the correction of cognitive and emotional disorders in patients with chronic cerebral ischemia. Russian Medical Journal. 2017;21:1507-10 (in Russian)].</mixed-citation></ref></ref-list></back></article>
